Organon & Co.
For the period ended Mar 31, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 2, 2025
OGN$13.89+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Income
(Unaudited, $ in millions except shares in thousands and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $1,513 | $1,622 |
| Cost of sales | 672 | 665 |
| Gross profit | 841 | 957 |
| Selling, general and administrative | 420 | 431 |
| Research and development | 96 | 112 |
| Acquired in-process research and development and milestones | 6 | 15 |
| Restructuring costs | 86 | 23 |
| Interest expense | 124 | 131 |
| Exchange (gains) losses | (4) | 6 |
| Other expense, net | 12 | 3 |
| Income before income taxes | 101 | 236 |
| Income tax expense | 14 | 35 |
| Net income | $87 | $201 |
| Earnings per share: | ||
| Basic | $0.34 | $0.78 |
| Diluted | $0.33 | $0.78 |
| Weighted average shares outstanding: | ||
| Basic | 257,862 | 255,695 |
| Diluted | 261,001 | 258,362 |
-3-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.